Start your trial An Advanced GLP-1 Program A dual-pathway GLP-1 to lose the weight and a personalized plan to keep it off
A phase 2 clinical trial, published in The New England Journal of Medicine, included 338 adults with a body mass index (BMI) of 30 or greater, or a BMI between 27 and 30, with at least one weight-related comorbidity to assess the efficacy and benefits of retatrutide
The mechanisms of GLP-1 RAs action in retinopathy and NAION remain incompletely understood, highlighting the need for large trials with baseline retinal grading and extended follow-up
The triple-agonist mechanism that delivers superior metabolic efficacy also demands sophisticated dosing strategies that navigate complex dose-response relationships across three distinct receptor systems
It does not affect platelet function or coagulation pathways, so the combination does not inherently increase haemorrhagic complications beyond the baseline risk of anticoagulation therapy alone
These medications typically arent recommended while breastfeeding, either